COPD-X Australian guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2022 update

Eli Dabscheck*, Johnson George, Kelcie Hermann, Christine F. McDonald, Vanessa M. McDonald, Renae McNamara, Mearon O’Brien, Brian Smith, Nicholas A. Zwar, Ian A. Yang

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)


Introduction: Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease characterised by persistent respiratory symptoms and chronic airflow limitation on spirometry. COPD is highly prevalent and is associated with exacerbations and comorbid conditions. “COPD-X” provides quarterly updates in COPD care and is published by the Lung Foundation Australia and the Thoracic Society of Australia and New Zealand. 

Main recommendations: The COPD-X guidelines (version 2.65) encompass 26 recommendations addressing: case finding and confirming diagnosis; optimising function; preventing deterioration; developing a plan of care; and managing an exacerbation. 

Changes in management as a result of these guidelines: 

Both non-pharmacological and pharmacological strategies are included within these recommendations, reflecting the importance of a holistic approach to clinical care for people living with COPD to delay disease progression, optimise quality of life and ensure best practice care in the community and hospital settings when managing exacerbations. Several of the new recommendations, if put into practice in the appropriate circumstances, and notwithstanding known variations in the social determinants of health, could improve quality of life and reduce exacerbations, hospitalisations and mortality for people living with COPD.

Original languageEnglish
Pages (from-to)415-423
Number of pages9
JournalMedical Journal of Australia
Issue number8
Publication statusPublished - 17 Oct 2022


Dive into the research topics of 'COPD-X Australian guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2022 update'. Together they form a unique fingerprint.

Cite this